CERTIFICATE OF ANALYSIS

Product Details

Product name:	Anti-CD3 & CD20 Reference Antibody (Epcoritamab)	Lot.No.:	P248574C-P248575C-2
Target:	CD20, CD3	Catalog:	CHBA008
Target Accession:	P07766 & P11836	Concentration :	1 mg/mL
Clonality:	Bispecific	Isotype:	IgG-like
Reactivity:	Human	Molecular Weight (kDa) :	146.28 kDa
Application:	Kinetics (SPR), ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	＜1 EU/mg
Formulation:	Liquid：100mM Pro-Ac, 20mM Arg pH 5.0 Lyophilization: 25mM histidine, 8% sucrose, 0.01% Tween80 pH6.2	Conjugation:	Unconjugated
Reconstitution:	For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.	Expression System:	CHO
Storage:	Upon receipt, store immediately at -20°C or lower for 24 months. Store aliquots at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.	Purification:	Protein A

Data

Purity: SDS-PAGE



Anti-CD3 & CD20 Reference Antibody (Epcoritamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity: SEC-HPLC



The purity of Anti-CD3 & CD20 Reference Antibody (Epcoritamab) is more than 99.00%, determined by SEC-HPLC.

Bioactivity: FACS



Epcoritamab bound to CD3e protein, and then rebounded to secondary antibodies (Anti-human-κ+λ-HRP) , and read OD450. As shown in fig, Epcoritamab bound to hu-CD3e-Fc, and the EC50 was 0.024 nM.

ELISA



Epcoritamab bound to CD20 protein, and then rebounded to secondary antibodies (Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Epcoritamab bound to hu-CD20-VLP, and the EC50 was 0.095 nM.

Tel: +86 021 3368 1627 Email: service@sanyoubio.com Web: www.crs.sanyoubio.com

CERTIFICATE OF ANALYSIS

Bioactivity: FACS



Epcoritamab bound to huCD3e-jurkat cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Epcoritamab bound to huCD3e-jurkat cells, and the EC50 was 18.920 nM.

Bioactivity: FACS



Epcoritamab bound to Raji cells, and then rebounded to fluorescent secondary antibodies (Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Epcoritamab bound to Raji cells, and the EC50 was 8.393 nM.

Function: Luciferase



Co-incubation of Epcoritamab with Jurkat cells, then with the addition of Raji cells for 6 hours. Bright-Lite was used to detect the fluorescent signal.As shown in fig, Epcoritamab was able to activate the NF-AT signaling pathway, and the EC50 was 0.009 nM.

Tel: +86 021 3368 1627 Email: service@sanyoubio.com Web: www.crs.sanyoubio.com